It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cell plasticity, changes in cell fate, is crucial for tissue regeneration. In the lung, failure of regeneration leads to diseases, including fibrosis. However, the mechanisms governing alveolar cell plasticity during lung repair remain elusive. We previously showed that PCLAF remodels the DREAM complex, shifting the balance from cell quiescence towards cell proliferation. Here, we find that PCLAF expression is specific to proliferating lung progenitor cells, along with the DREAM target genes transactivated by lung injury. Genetic ablation of Pclaf impairs AT1 cell repopulation from AT2 cells, leading to lung fibrosis. Mechanistically, the PCLAF-DREAM complex transactivates CLIC4, triggering TGF-β signaling activation, which promotes AT1 cell generation from AT2 cells. Furthermore, phenelzine that mimics the PCLAF-DREAM transcriptional signature increases AT2 cell plasticity, preventing lung fibrosis in organoids and mice. Our study reveals the unexpected role of the PCLAF-DREAM axis in promoting alveolar cell plasticity, beyond cell proliferation control, proposing a potential therapeutic avenue for lung fibrosis prevention.
Cell plasticity, changes in cell fate, is involved in tissue regeneration. Here, Kim et al. show that PCLAF-DREAM-driven alveolar cell plasticity is crucial for lung regeneration and targetable as a preventative strategy for lung fibrosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 The University of Texas MD Anderson Cancer Center, Department of Experimental Radiation Oncology, Division of Radiation Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
2 The University of Texas MD Anderson Cancer Center, Department of Pulmonary Medicine, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
3 Boston Children’s Hospital, Stem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438)
4 University of Virginia, Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, USA (GRID:grid.27755.32) (ISNI:0000 0000 9136 933X)
5 The University of Texas MD Anderson Cancer Center, Department of Experimental Radiation Oncology, Division of Radiation Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, Graduate School of Biomedical Sciences, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, Program in Genetics and Epigenetics, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)